EGFR-IN-126 (compound 9d) is a potent small molecule inhibitor targeting the EGFR L858R/T790M/C797S triple mutant, with an IC50 of 5 nM. It demonstrates robust antitumor efficacy in both cellular assays and animal models, making it a valuable chemical probe for studying resistant non-small cell lung cancer (NSCLC).